Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead CEO Comments on Recent Nasdaq Letter

Abstract:
Arrowhead Research Corporation's (NASDAQ: ARWR) ("the Company") President and Chief Executive Officer today issued the following open letter to the Company's shareholders:

Arrowhead CEO Comments on Recent Nasdaq Letter

PASADENA, CA | Posted on February 18th, 2009

Dear Shareholders:

On Friday, February 13, we announced that we had received a letter from the Nasdaq Stock Market ("Nasdaq") informing us that Arrowhead has fallen below the minimum stockholder equity requirement for the Nasdaq Global Market and that our listing is currently under review. Based on stockholder inquiries received by the Company today, I wanted to provide additional information about the review process and what this means for Arrowhead.

During the review period, Arrowhead common stock will continue to trade on the Nasdaq Global Market. Under Nasdaq rules, Arrowhead may submit a formal plan to regain compliance with Nasdaq Global Market continued listing standards on or before February 26, 2009, and we are currently preparing the submission. If the plan is accepted, Nasdaq can grant the Company a 105-day extension to regain compliance.

Should the Nasdaq not accept our compliance plan, we would seek to transfer the listing of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market. The Nasdaq Capital Market is one of the three market tier designations for Nasdaq-listed stocks and operates in substantially the same manner as the Nasdaq Global Market, although it has a lower stockholder equity requirement than the Nasdaq Global Market.

We remain optimistic about our business in these challenging times, and we believe that we will be able to continue our progress whether our stock is listed on the Nasdaq Global Market or the Nasdaq Capital Market.

I invite all investors to listen to the conference call for an in-depth review of Arrowhead and its subsidiaries' growth catalysts and market opportunity. An archive of the First Quarter Fiscal 2009 conference call is located at the following link:
phx.corporate-ir.net/playerlink.zhtml?c=120497&s=wm&e=2084013.

On behalf of Arrowhead, we look forward to your continued support.
Sincerely,
Christopher Anzalone
Chief Executive Officer

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and investments in two minority-owned subsidiaries.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed in strengthening our balance sheet or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.

For more information, please click here

Contacts:
Virginia Dadey
212-514-3707

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024

NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024

Innovative sensing platform unlocks ultrahigh sensitivity in conventional sensors: Lan Yang and her team have developed new plug-and-play hardware to dramatically enhance the sensitivity of optical sensors April 5th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024

Innovative sensing platform unlocks ultrahigh sensitivity in conventional sensors: Lan Yang and her team have developed new plug-and-play hardware to dramatically enhance the sensitivity of optical sensors April 5th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

A simple, inexpensive way to make carbon atoms bind together: A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules, which are critical for drug development April 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project